Search research articles
Contact Us
Filters
Showing results (121-130 of 168) with videos related to
Page
of 17
Sort By:
Cancer Chemotherapy and Pharmacology
|
November 10, 2017
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia
Ashkan Emadi, Jennie Y Law, Erin T Strovel, et al.
Blood Advances
|
September 23, 2022
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
Amir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
JAMA Oncology
|
December 17, 2020
Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial
Areej El-Jawahri, Thomas W LeBlanc, Alison Kavanaugh, et al.
Blood
|
October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Amir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Blood Advances
|
February 27, 2025
Integrative cytogenetic and molecular studies unmask "chromosomal mimicry" in hematologic malignancies
Melissa Zhao, Scott Ryall, Samuel J Brody, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 2, 2014
Chronic myelogenous leukemia, version 1.2015
Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Cancer
|
November 14, 2018
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia
Andrew M Brunner, Donna S Neuberg, Seth A Wander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Amir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
The New England Journal of Medicine
|
June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Gail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
Blood
|
June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
Stéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 168) with videos related to
Sort By:
Page
of 17
Cancer Chemotherapy and Pharmacology
|
November 10, 2017
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia
Ashkan Emadi, Jennie Y Law, Erin T Strovel, et al.
Blood Advances
|
September 23, 2022
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
Amir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
JAMA Oncology
|
December 17, 2020
Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial
Areej El-Jawahri, Thomas W LeBlanc, Alison Kavanaugh, et al.
Blood
|
October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Amir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Blood Advances
|
February 27, 2025
Integrative cytogenetic and molecular studies unmask "chromosomal mimicry" in hematologic malignancies
Melissa Zhao, Scott Ryall, Samuel J Brody, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 2, 2014
Chronic myelogenous leukemia, version 1.2015
Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
Cancer
|
November 14, 2018
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia
Andrew M Brunner, Donna S Neuberg, Seth A Wander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2023
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Amir T Fathi, Haesook T Kim, Robert J Soiffer, et al.
The New England Journal of Medicine
|
June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Gail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
Blood
|
June 17, 2022
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
Stéphane de Botton, Pau Montesinos, Andre C Schuh, et al.
Page
of 17